Efficacy News and Research

RSS

Polarized filter may improve ability to detect precancerous changes, reduce unnecessary biopsies

The same filtered light that enables sunglasses to reduce glare may improve a physician's ability to detect early signs of cervical cancer, reducing unnecessary biopsies and surgery.

30 Nov 2011

Study examines alternative immunization schedule occurrence rates in Washington State

Seventy-seven percent of Washington state pediatricians report that they are sometimes or frequently asked to provide alternative childhood vaccine schedules for their patients, according to a new study from Seattle Children's Research Institute. Researchers also found that 61 percent of Washington state pediatricians are comfortable using an alternative schedule when asked by a parent.

30 Nov 2011

Scientists create genetically-altered neurons that light up as they fire

In a scientific first that potentially could shed new light on how signals travel in the brain, how learning alters neural pathways, and might lead to speedier drug development, scientists at Harvard have created genetically-altered neurons that light up as they fire.

30 Nov 2011

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

29 Nov 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

Pediatricians frequently asked to provide alternative childhood vaccine schedules

29 Nov 2011

Critical breakthrough in development of treatment for Duchenne Muscular Dystrophy

Academics from Royal Holloway, University of London and a team lead by scientists at the UCL Institute of Child Health (ICH), have made an important breakthrough in the development of a treatment for Duchenne Muscular Dystrophy (DMD) which in the future could help the likes of the Lloyd family who were featured on last night's X-Factor show.

29 Nov 2011

VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa

VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - has stopped testing the gel.

29 Nov 2011

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

Inviragen commences DENVax Phase 2 trial for dengue

Inviragen, Inc. today announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

28 Nov 2011

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Inspiration Biopharmaceuticals, Inc. today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.

28 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for further evaluation of cabozantinib, Exelixis' lead compound, in a variety of solid tumors.

28 Nov 2011

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

25 Nov 2011

HGNS increases airflow during sleep in patients with OSA

Hypoglossal nerve stimulation (HGNS) produced marked dose-related increases in airflow in obstructive sleep apnea (OSA) patients without arousing them from sleep, according to a new study from the Johns Hopkins Sleep Disorders Center.

25 Nov 2011

AMP opposes NIH proposal to license cancer-related proteonomics patent

The Association for Molecular Pathology (AMP) opposed the National Institutes of Health (NIH) proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.

23 Nov 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277-) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way.

23 Nov 2011

Arginine may reactivate T-cells in patients with glioblastoma

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis.

22 Nov 2011

Efficacy News and Research

Polarized filter may improve ability to detect precancerous changes, reduce unnecessary biopsies

Study examines alternative immunization schedule occurrence rates in Washington State

Scientists create genetically-altered neurons that light up as they fire

FDA assigns priority-review designation for ELIQUIS NDA for stroke prevention in atrial fibrillation

BioLineRx reports third quarter net loss of NIS 7.9 million

Pediatricians frequently asked to provide alternative childhood vaccine schedules

Critical breakthrough in development of treatment for Duchenne Muscular Dystrophy

VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Inviragen commences DENVax Phase 2 trial for dengue

Inspiration commences enrollment in second OBI-1 Accur8 clinical trial program for congenital hemophilia A

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

HGNS increases airflow during sleep in patients with OSA

AMP opposes NIH proposal to license cancer-related proteonomics patent

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

Arginine may reactivate T-cells in patients with glioblastoma

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News